Research continues to investigate cures for Alzheimer’s, as scientists believe new drug ‘could slow down rate at which disease progresses.’ (BBC).
Biogen reveals that the new drug Aducanumab could benefit those with Alzheimer’s but cannot cure the disease. With a larger data set the company has now found that with higher doses of the drug we can potentially slow down the progression of Alzheimer’s.
At Guild Living, we believe until there is a cure for the disease, we must work to improve the lives of those with Alzheimer’s and enable those in the third age to enjoy their later life. ‘I believe that our role for the next 10 years whilst cures are still being found is to enable people who develop different forms of Alzheimer’s be it dementia, to live the best life they can’, says Eugene Marchese Founder and CEO at Guild Living.
READ MORE: REALITIES OF LOSING A LOVED ONE TO DEMENTIA.
‘Once we understand that someone has been identified as having dementia we can then deal with it in a way that slows it down and allows people to live their best life’, adds Marchese
At Guild Living ‘we will develop programmes around dementia awareness and incorporate innovative ways of designing communities from wayfinding to cognitive stimulation. This will help to ensure that loneliness doesn’t take over and that people with dementia don’t retreat.’, explains Marchese.
BBC visited University College of London to discover how the drug works. Watch the video to find more.